

2019 Future of Nicotine Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2AEBFA56A0EEN.html>

Date: February 2019

Pages: 60

Price: US\$ 2,199.00 (Single User License)

ID: 2AEBFA56A0EEN

Abstracts

The global demand for Nicotine Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Nicotine Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Nicotine Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Nicotine Addiction Report Description-

The 2019 pipeline study on Nicotine Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Nicotine Addiction pipeline compounds.

The Nicotine Addiction pipeline guide presents information on all active drugs currently being developed for Nicotine Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Nicotine Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Nicotine Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Nicotine Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Nicotine Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Nicotine Addiction pipeline report includes-

An overview of Nicotine Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Nicotine Addiction pipeline

Company wise list of Nicotine Addiction pipeline

Mechanism of Action wise Nicotine Addiction pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Nicotine Addiction pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Nicotine Addiction pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Nicotine Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL NICOTINE ADDICTION PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Nicotine Addiction Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Nicotine Addiction pipeline, H1- 2019
- 3.5 Mechanism of Action wise Nicotine Addiction Pipeline Candidates

4 ADDEX THERAPEUTICS LTD NICOTINE ADDICTION PIPELINE DETAILS

- 4.1 Addex Therapeutics Ltd Business Profile
- 4.2 Addex Therapeutics Ltd Nicotine Addiction Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ANTIDOTE THERAPEUTICS INC NICOTINE ADDICTION PIPELINE DETAILS

- 5.1 Antidote Therapeutics Inc Business Profile
- 5.2 Antidote Therapeutics Inc Nicotine Addiction Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ASSUAGE PHARMACEUTICALS INC NICOTINE ADDICTION PIPELINE DETAILS

- 6.1 Assuage Pharmaceuticals Inc Business Profile
- 6.2 Assuage Pharmaceuticals Inc Nicotine Addiction Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ASTRAEA THERAPEUTICS LLC NICOTINE ADDICTION PIPELINE DETAILS

- 7.1 Astraea Therapeutics LLC Business Profile
- 7.2 Astraea Therapeutics LLC Nicotine Addiction Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 CAMINO PHARMA LLC NICOTINE ADDICTION PIPELINE DETAILS

- 8.1 Camino Pharma LLC Business Profile
- 8.2 Camino Pharma LLC Nicotine Addiction Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 CHRONOS THERAPEUTICS LTD NICOTINE ADDICTION PIPELINE DETAILS

- 9.1 Chronos Therapeutics Ltd Business Profile
- 9.2 Chronos Therapeutics Ltd Nicotine Addiction Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CV SCIENCES INC NICOTINE ADDICTION PIPELINE DETAILS

- 10.1 CV Sciences Inc Business Profile
- 10.2 CV Sciences Inc Nicotine Addiction Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 DEMERX INC NICOTINE ADDICTION PIPELINE DETAILS

- 11.1 DemeRx Inc Business Profile
- 11.2 DemeRx Inc Nicotine Addiction Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 EOLAS THERAPEUTICS INC NICOTINE ADDICTION PIPELINE DETAILS

- 12.1 Eolas Therapeutics Inc Business Profile
- 12.2 Eolas Therapeutics Inc Nicotine Addiction Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 HEPTARES THERAPEUTICS LTD NICOTINE ADDICTION PIPELINE DETAILS

- 13.1 Heptares Therapeutics Ltd Business Profile
- 13.2 Heptares Therapeutics Ltd Nicotine Addiction Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 INDIVIOR PLC NICOTINE ADDICTION PIPELINE DETAILS

14.1 Indivior Plc Business Profile

14.2 Indivior Plc Nicotine Addiction Drug Details

14.3 Drug Snapshot

14.3.1 Originator

14.3.2 Collaborator/Co-Developer

14.3.3 Route of Administration

14.3.4 Orphan Drug/Fast Track/Special Designation

14.3.5 Geography

14.3.6 Type of Molecular Entity

14.3.7 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15 MAKSCIENTIFIC LLC NICOTINE ADDICTION PIPELINE DETAILS

15.1 MAKScientific LLC Business Profile

15.2 MAKScientific LLC Nicotine Addiction Drug Details

15.3 Drug Snapshot

15.3.1 Originator

15.3.2 Collaborator/Co-Developer

15.3.3 Route of Administration

15.3.4 Orphan Drug/Fast Track/Special Designation

15.3.5 Geography

15.3.6 Type of Molecular Entity

15.3.7 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 MULTIMERIC BIOTHERAPEUTICS INC NICOTINE ADDICTION PIPELINE DETAILS

- 16.1 Multimeric Biotherapeutics Inc Business Profile
- 16.2 Multimeric Biotherapeutics Inc Nicotine Addiction Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 OMEROS CORP NICOTINE ADDICTION PIPELINE DETAILS

- 17.1 Omeros Corp Business Profile
- 17.2 Omeros Corp Nicotine Addiction Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 SAVANT HWP INC NICOTINE ADDICTION PIPELINE DETAILS

- 18.1 Savant HWP Inc Business Profile
- 18.2 Savant HWP Inc Nicotine Addiction Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer

- 18.3.3 Route of Administration
- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 SELECTA BIOSCIENCES NICOTINE ADDICTION PIPELINE DETAILS

- 19.1 Selecta Biosciences Business Profile
- 19.2 Selecta Biosciences Nicotine Addiction Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. LATEST NICOTINE ADDICTION DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Nicotine Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2AEBFA56A0EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2AEBFA56A0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

